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background: The aim of this study is to identify the long-term outcomes (all-cause mortality and sudden cardiac death (SCD)) after medical 
therapy, alcohol septal ablation (ASA) or myectomy in patients with hypertrophic cardiomyopathy (HCM).
Methods: In this international multi-center study 1065 consecutive HCM patients (age 52 ± 16 years, 61% male) were included. A total of 716 
(67%) had a left ventricular outflow tract gradient ≥30 mmHg, of them 142 (20%) patients were treated medically, 321 (45%) patients underwent 
ASA and 253 (35%) patients underwent myectomy. Primary endpoints were all-cause mortality and SCD (including resuscitated cardiac arrests, and 
appropriate internal converter defibrillator shocks). Kaplan-Meier graphs and Cox-regression models were used for statistical analyses.
results: During a median follow-up of 6.5 (3.4-10.7) years, annual mortality rates were similar in medically treated patients in NYHA class I/II 
(2.2%), ASA patients (1.9%), myectomy patients (1.9%), and non-obstructive HCM patients (1.6%). Annual SCD-rate was low after invasive therapy: 
0.81% in the ASA group, and 0.46% in the myectomy group. Multivariable analysis demonstrated that the risk of SCD was lower after myectomy 
compared with the ASA group (HR 0.36 [0.14-0.91], p=0.03), and the medical group (HR 0.34 [0.14-0.91], p=0.03).
conclusions: In experienced centers, patients with obstructive HCM treated with ASA, myectomy, and medical therapy when asymptomatic or 
mildly symptomatic, all had an excellent survival that was similar to that of non-obstructive HCM patients. The long term risk of SCD is low after ASA 
and myectomy, especially patients who underwent myectomy had a favourable outcome.
